Alternative Products Expo: Innovation and Sustainability

Financial analysts, savvy investors, business owners, researchers, and pioneers, are invited to attend Alternative Products Expo to be held at the World Market Center, Las Vegas from September 14-16, 2023. Las Vegas plays host to thousands of esteemed events every year, and there are several reasons for this: state-of-the-art hospitality, top-notch facilities, year-round sunshine, and world-class dining and entertainment options. Featuring one-of-a-kind nightlife, the city never fails to provide a memorable experience for the attendees.

Alternative Products Expo (AltPro Expo) promises to deliver unique networking opportunities for customers and businesses alike. The highly anticipated event has earned a reputation for offering an incredible platform for business owners to showcase their unique and sustainable products. As the countdown for this innovative Expo begins, attendees can expect an unmatched experience packed with actionable insights from the industry leaders.

Exciting Opportunities for Forward-Thinking Businesses

Pioneered by a group of socially responsible entrepreneurs, the Alternative Products Expo is committed to connecting revolutionary businesses with health-conscious customers. The expo will feature a wide range of eco-friendly and innovative products, ranging from plant-based foods, and renewable energy technologies, to sustainable packaging solutions and ethical fashion items. They will witness innovative demos and learn of the latest product launches that will shape a sustainable future and reduce the environmental footprint at a global level.

The AltPro Expo provides customers with a unique opportunity to buy products that contribute to an eco-friendly planet. The organizers will implement sustainable practices throughout the Expo to ensure the targeted audience aligns with their values. Attendees will get a unique opportunity to network with like-minded entrepreneurs and potential investors who will share their passion for innovation. By attending thought-provoking seminars and panel discussions, they will get insights into the latest trends and best practices in the alternative products industry.

To learn more, please visit https://cnw.fm/A8zIE.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Study Finds Psychosis-Prone Young People Registered Surprising Symptom Improvement After Using Marijuana

A team of researchers from several institutions has discovered that cannabis may improve symptoms in teenagers and young adults at risk of developing psychosis. The study contradicts claims that marijuana use can trigger the early onset of psychotic disorder symptoms and shows that cannabis may actually deliver modest cognitive functioning improvements while reducing the use of prescribed medications.

Researchers at the Stanford University School of Medicine, Zucker Hillside Hospital, University of California at Davis and the University of Michigan published their findings in the “Psychiatry Research” journal. The study noted that the recent surge in recreational cannabis use has raised questions regarding the possibility of adult use being a trigger for the onset of psychosis.

However, the study authors note that there is little evidence tying cannabis use and negative health outcomes for people who are predisposed to developing psychosis.

The research team followed 210 patients with a clinical high risk (CHR) of psychosis who took part in an Early Detection and Intervention for the Prevention of Psychosis Program (EDIPPP) for two years. Over the study period, the researchers compared prescription medication use with mental health in people who consumed cannabis regularly and people who didn’t consume cannabis.

Individuals who consumed cannabis continually over the two-year study period did not exhibit an increased psychosis transition rate, study authors say, and cannabis use did not contribute to a decline in clinical symptoms, neurocognition or functioning levels. On the contrary, youth who used cannabis continuously exhibited improved clinical symptoms even as their medication use decreased.

Furthermore, the scientists found that CHR youth who used cannabis regularly over the study period had higher social functioning and neurocognition compared to noncannabis users. The recent study adds to the growing body of scientific literature on cannabis and its potential association with psychosis.

Cannabis legalization opponents have long claimed that cannabis use can trigger schizophrenia, especially now that the market is flooded with increasingly potent THC-infused products. Some medical professionals have also stated that continued exposure to high-THC cannabis may cause psychosis-like symptoms in some consumers.

Studies have found that cannabis-induced psychosis is quite rare, with a Canadian study that analyzed 23,000 consumers finding that only 26 individuals required hospitalization for psychotic-like symptoms. Data from Canada also shows that although the country legalized adult-use cannabis in 2018, there has been no significant increase in the number of emergency room visits due to cannabis-induced schizophrenia or psychosis.

Additionally, a European study published in the “Translation Psychiatry” journal found that less than one-half of 1% of 230,000 consumers experienced psychosis-like symptoms after consuming cannabis.

As the different misconceptions about marijuana are dispelled one at a time, demand for the substance is likely to increase and enterprises such as Advanced Container Technologies Inc. (OTC: ACTX), which capitalize on availing some of the products that marijuana cultivators need, could grow their businesses.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — How Cannabis Can Help with Oral Health

Cannabis has attracted a lot of attention in recent years due to its potent and rather versatile therapeutic properties. States with medical cannabis programs allow patients suffering from at least one out of more than 20 qualifying conditions to use cannabis for therapeutic purposes, indicating marijuana’s wide range of medical applications.

Furthermore, researchers are constantly working to further cannabis science and understand precisely how it delivers its benefits to develop safe cannabis-derived medications for various health issues. Surprisingly, cannabis may also have some applications in oral health, particularly in terms of managing dental pain and anxiety.

It is a known fact that cannabis can be effective against chronic pain. A large portion of recreational users and medical cannabis patients use the plant to address pain-related conditions. Furthermore, researchers have noted a possible reduction in opioid prescriptions in states with legal cannabis markets as people turn to cannabis as an alternative for pain relief.

This makes cannabis a possible option for alleviating pain caused by dental issues. The Centers for Disease Control and Prevention (CDC) estimates that more than 40% of U.S. adults experience some kind of dental pain every year. In extreme cases, dental pain can cause or exacerbate mental issues, including depression, and significantly reduce an individual’s quality of life. Although cannabis may be a temporary solution to most dental issues, it has the ability to inhibit pain of most kinds and could be helpful in treating dental pain.

Cannabis extract CBD (cannabidiol) is specifically known for its pain-relieving properties, especially when paired with another extract called THC (delta-9 tetrahydrocannabinol). CBD also has anti-inflammatory and antioxidant properties that could make it effective at treating and promoting the healing of common dental conditions like canker sores.

Some cannabinoids have antibacterial properties that could allow for the development of cannabis-based products to minimize the effects of dangerous oral bacteria and reduce the risk of oral diseases. On top of that, marijuana’s anti-anxiety effects at low doses can also help to alleviate the anxiety many people feel before a dentist appointment.

Around 36% of Americans are estimated to have a fear of dental treatment, and 12% report having an extreme fear of dental treatments. Given how important regular dental appointments are to maintaining dental health and overall physical and mental health, it is crucial that everyone visits a dentist at least once every year for a checkup.

For people with anxiety prior to dentist visits, cannabis can help alleviate their anxiety, calm their fears and allow them to successfully complete dental exams.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Registration for Medical Marijuana Cards in South Dakota Nearly Doubles State Projections

More than two years have passed since the legalization of medical cannabis in South Dakota, and an impressive count of more than 11,500 individuals from the state now possess medical marijuana cards. This substantial figure stands in stark contrast to the initial projections made back in 2021 when the program was launched, as Jennifer Seale, the medical cannabis program administrator at the state Department of Health, pointed out.

Initially, the state had envisaged a cardholder count of 6,000 by 2024, a projection that Seale shared with the members of the Medical Cannabis Oversight Committee in Pierre during a recent session. The committee, composed of lawmakers and other officials, evaluates the state-operated medical cannabis program and provides suggestions for its enhancement.

The fiscal year 2023 witnessed a significant portion of the medical cannabis program’s revenue attributed to newly issued cards, amassing a total of $1.37 million. However, Seale expressed uncertainty about the sustainability of this revenue stream once the issuance of medical cannabis cards reaches a saturation point.

A contentious issue that emerged in discussions pertains to pop-up clinics, which have become a primary channel through which South Dakotans access medical cannabis cards. The issue of pop-up clinics was also flagged as problematic during a prior committee assembly in October 2022. This concern led to the introduction of failed bills, one of which aimed to confine medical cannabis clinics to specific facilities.

Representative Fred Deutsch presented these bills during the legislative session of 2023, which concluded in March. Reflecting on his personal experience of acquiring a medical cannabis card, Deutsch underscored the lack of privacy due to audibly overheard conversations between patients and providers. Additionally, he highlighted the suboptimal nature of the provider-patient relationship established during the appointment. Deutsch’s appointment was conducted by a nurse practitioner he had not encountered before. He criticized the appointment for its brevity, lasting less than 10 minutes, and for failing to conduct a thorough examination to determine his eligibility for the card.

The committee is poised to readdress the issue, potentially through legislation or recommendations presented to the Legislature. Several ideas are under consideration, including barring individuals with vested interests in the cannabis industry from operating pop-up clinics, mandating ongoing medical education for card issuance and implementing a cap on the number of cards a provider can issue in a single day.

Although the fee for obtaining a medical cannabis card remains at $75, pop-up clinics have the latitude to impose significantly higher charges for appointments. As Deutsch disclosed, he paid around $170 for his appointment.

Presently, there is no limitation on the number of cards a provider can dispense. Senator Erin Tobin, who chairs the committee, asserted that enforcing such a change would eliminate the financial incentive associated with operating pop-up clinics.

The committee’s discussions extended to other matters, including the utilization of medical cannabis by parolees, even though substances such as alcohol are prohibited for them. Some members of the committee contended that this allowance contradicts the court’s intention of barring parolees from alcohol or drug use. The committee has plans to revisit the topic of pop-up clinics and other associated issues in its forthcoming meeting.

The growing interest in the medical use of marijuana could encourage many companies such as Advanced Container Technologies Inc. (OTC: ACTX) to expand their operations and address the growing demand for cultivation equipment and other supplies needed in the marijuana value chain.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Why Canadian MJ Companies Are Increasingly Flagging Each Other for Noncompliance

An escalating number of Canadian marijuana enterprises are submitting grievances against their industry counterparts, alleging infractions or expressing concerns. This escalating trend is a product of fierce rivalry and struggling companies resorting to any available advantage, as experts point out.

According to Canada’s federal marijuana regulatory authority, the past year witnessed 706 instances of such grievances filed by regulated marijuana establishments against fellow regulated operators. This figure represents a notable surge compared to the records from 2021, which documented 214 formal complaints, and the statistics from 2020, when the count stood at 182 complaints, as data from Health Canada showed.

Chad Finkelstein, a legal expert at the Toronto-based law firm Dale and Lessmann, commented on the situation, noting that “numerous cannabis enterprises engage in various marketing practices that border on regulatory conformity or, in some instances, overtly violate them.”

In a recent example, an Alberta-based cannabis retailer was found to have transgressed the advertising criteria laid out by the province’s Cannabis, Liquor, and Gaming Commission. Finkelstein noted that previously, cannabis companies habitually scrutinized each marketing concept in advance to ensure compliance. However, fewer firms follow this practice today. He suggested this shift might be due, in part, to the historical lack of enforcement against potentially contentious marketing actions, leading marijuana companies to perceive these as permissible.

Finkelstein, who also chairs the firm’s marijuana division, advised companies to heed feedback from the public. “The optimal approach to risk mitigation involves avoiding platforms more likely to attract family or parental attention,” he advised. “We’ve encountered clients who desired to take calculated risks with advertising during festivals or via mailers potentially seen by minors. If your target audience includes families, there’s a higher likelihood of receiving grievances compared to instances where exposure to children is limited, and parents are less predisposed to field inquiries from their children regarding the presence and meaning of the content.”

Hyde Advisory and Investments CEO David Hyde affirmed that there is an increasing number of distressed licensed producers, resulting in heightened complaints lodged against rival enterprises. He noted that licensed producers struggling to differentiate themselves often resort to questionable measures to gain an edge over competitors.

“Many are forced to navigate advertising restrictions, skirt sampling limitations, or even offer incentives to retailers — whatever it takes, as many have realized that pushing boundaries and taking risks is essential,” he said.

This has prompted their competitors, which are also teetering on the brink, to cry foul, even if they aren’t actually breaching regulations or crossing boundaries, simply because they are just as desperate.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

NECANN’s 4th Annual New Jersey Cannabis Convention Is The Perfect Setting to Learn Everything about the Cannabis Industry

The largest B2B cannabis industry event in New Jersey – NECANN’s New Jersey Cannabis Convention – returns to Atlantic City on September 8-9, 2023. Now in its 4th year, the event, which is part of the largest cannabis and hemp convention series in the world, continues to grow as the New Jersey cannabis market develops. It comes more than a year after the state legalized the sale of recreational marijuana, which led to the April 2023 opening of the first licensed recreational marijuana dispensary in Atlantic City (https://cnw.fm/KVDTv).

With such stores finally opening and the number of licenses rapidly increasing, the number of ancillary businesses, entrepreneurs, investors, cultivators, medical dispensaries, license holders, and suppliers, is increasing by the day. Conveniently, NECANN’s New Jersey Cannabis Convention is designed for this category of budding industry players and entrants, among others. The event represents everything that touches cannabis and promises to be the perfect setting for attendees to learn about the industry.

“There’s everything here that you could possibly learn about the cannabis industry. Everything from grow lights, payment processors, banking, [and] accounting. If you are looking to start any type of cannabis business, you can come to NECANN and learn whatever you are trying to learn,” said Brian O’Connor of Paybotic, a payment processor that enables cannabis businesses to transact, in a video recapping the 2021 event (https://cnw.fm/HJvmM).

What makes the New Jersey Cannabis Convention particularly appealing to startups is the fact that it is an opportunity to meet similar sprouting businesses. Even so, the event is equally suited for exhibitors drawn from every niche within the cannabis industry. Attracting thousands of cultivators, industry professionals, educators, and advocates, from hundreds of local and national companies, the New Jersey Cannabis Convention promises a lot of foot traffic, much to the advantage of vendors and businesses showcasing their products. In fact, exhibitors who were part of previous editions of the event have lauded its role in bringing them closer to investors and potential business partners. The 2023 event will be no different, so reserve your exhibit space today.

For attendees in pursuit of knowledge, there’s more! The activity-packed two-day event features learnings from expert speakers delivered through dozens of planned sessions. Moreover, there are plenty of networking opportunities. The New Jersey Cannabis Convention is the perfect setting to learn, meet, and network. So do not miss it – register today.

For more information, please visit https://cnw.fm/DiUCt

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Court Ruling Puts New York’s Cannabis Equity Program in Jeopardy

Efforts to launch an equitable recreational cannabis industry in New York hit another roadblock after a state Supreme Court judge ruled that the licensing process violated state law. The most recent state Supreme Court ruling has now deemed the licensing process for social equity applicants unconstitutional and banned the state Office of Cannabis Management from providing any new retail recreational cannabis licenses until Aug. 25, 2023, when there will be further arguments on the matter.

Like other states with recreational cannabis markets, New York sought to launch an industry that provided equitable access to victims of the failed drug war via social-equity processes such as getting the first crack at the state’s first batch of adult-use cannabis retail licenses. However, a group of disabled veterans looking to enter the nascent cannabis market challenged the preferential licensing process for social-equity applicants in a state Supreme Court lawsuit.

The veterans argued that the Office of Cannabis Management violated state law by only allowing individuals with cannabis-related offenses and their immediate family members to apply for cannabis licenses rather than opening the application process to everyone. This lawsuit came months after multistate cannabis operators with medical marijuana licenses sued New York regulators for shutting them out of the recreational cannabis industry.

Although the ruling by Supreme Court Judge Kevin Bryant will not apply to individuals who had met the licensing conditions before Aug. 7, 2023, it will likely impact the hundreds of business owners looking to apply for Conditional Adult Use Retail Dispensary (CAURD) licenses.

CAURD permits are the only existing licenses for legal recreational cannabis sales in New York, meaning cutting access to these licenses essentially prevents entrepreneurs from entering the cannabis industry.

State regulators may have had their hearts in the right place in terms of social equity when they implemented the selective licensing program, but it has had major repercussions for the state adult-use cannabis market. According to the lawsuit filed by the disabled veterans, the New York Office of Cannabis Management has failed in its mandate to create the marijuana market “envisioned by the Marihuana Regulation and Taxation Act (MRTA),” particularly by preventing disabled military veterans and other minorities from access cannabis licenses.

The suit argued that every day that New York’s recreational cannabis program was limited to CAURD program participants impacted priority groups included in the MRTA as well as New York State farmers.

A spokesperson from the OCM said the agency will appeal the recent state Supreme Court ruling.

If these hiccups to the full launch of the recreational marijuana market in New York State continue, many opportunities are likely to be lost by entrepreneurs, such as those operating ancillary businesses similar to Advanced Container Technologies Inc. (OTC: ACTX).

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Medical Cannabis Firm Sues DEA Over Unjustifiable Licensing Delays

A medical marijuana company that focuses on developing cannabis-derived pharmaceuticals has filed a suit against the U.S. Drug Enforcement Administration (DEA) over “exponential delays” in the agency’s licensing process for cultivating medical research cannabis. MMJ BioPharma Cultivation sued the DEA in the U.S. Court of Appeals for the DC Circuit, claiming that the DEA’s licensing process, which can take several years, has prevented innovation which could help patients and which hamper the company’s business.

The Rhode Island-based medical cannabis company asked the federal court to compel the DEA into action and hopefully streamline its licensing process. MMJ said in its suit that although it began the licensing process in late 2017, several years of licensing delays have kept it from carrying out the research it was meant to do. The company is currently working to develop gel capsules with marijuana extracts to treat Huntington’s disease and multiple sclerosis (MS).

The DEA allowed MMJ to import cannabis for research from Canada, but the medical cannabis company ran into a wall when it applied for a license to cultivate cannabis for research purposes in-house rather than obtain it from Canada. According to MMJ, granting the company in-house cultivation privileges is “essential” to its ability to run clinical trials on the efficacy of cannabis against various health conditions.

MMJ added that without the ability to grow cannabis in-house to its own specifications, the company cannot develop a proper compound.

Its petition notes that it began the preregistration process for license application in June 2021 and went through several steps before a DEA diversion investigator informed MMJ officials they needed to wait for a final determination from DEA Headquarters. The petition claims MMJ did not receive a final determination from the DEA despite numerous follow-up attempts.

Furthermore, DEA personnel told MMJ officials that the agency still hadn’t made the final determination and they had “no idea” when the DEA would make the determination. According to the court filing, DEA personnel responded to subsequent inquiries on the progress of the final determination with statements such as, “Why do you want to know?” and “We’ll get to it when we get to it.”

MMJ states that the DEA still hasn’t made a final determination on its in-house cannabis cultivation license for research purposes for “some inexplicable reason,” even though the agency granted it a research license.

Company president Duane Boise argued in a press release that the DEA had failed its legislative mandate and pledged to get to the bottom of the issue.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — State Cannabis Regulators Urge Congress to Look Beyond CBD While Enacting Cannabinoid Regulations

State cannabis regulators are informing congressional legislators that, in addition to providing the FDA with more regulatory power, their investigation into the absence of federal regulations for CBD products derived from hemp must consider other cannabinoids that are becoming more widely available, such as delta-8 tetrahydrocannabinol.

Last Friday, the Cannabis Regulators Association (CANNRA) sent lawmakers a letter with proposals for developing a framework for all hemp-derived cannabinoids in reply to a request for expert advice on CBD laws from major Senate and House committees. The group members’ combined experience managing state cannabis initiatives served as the basis for the application.

While CBD has received a lot of attention, all derivatives other than delta-9 tetrahydrocannabinol, including psychoactive substances such as THC-O-acetate and delta-8 tetrahydrocannabinol, were also widely deregulated when hemp was legalized federally under the 2018 Farm Bill. CANNRA argued that Congress renamed marijuana as hemp and effectively legalized it on a federal level, with no restrictions on products.

Although the DEA has stated that it views cannabinoids as illegal if they are synthesized, which is typical for delta-8 tetrahydrocannabinol, the demand for these products has grown with little enforcement. Numerous states have acted on their own to outlaw or regulate them.

The FDA has been under fire from a number of legislators and hemp stakeholders for not enacting CBD regulations, but CANNRA stated that it concurs with the FDA that it does not currently have the jurisdiction to create the kind of complete framework required for a market this complicated. According to the regulators, the FDA requires precise authority and brief timeframes for issuing regulations.

Furthermore, the association recommended that the FDA work in tandem with tribes, territories and states to ensure that regulations are not created in isolation. And states ought to have the authority to pass laws that go above and beyond federal minimum requirements to better safeguard their citizens and businesses, even though federal regulations are crucial.

The letter also offers thorough answers to some 24 specific queries outlined by the committees on the matter. These questions covered a wide range of topics, from the state of the CBD market today to the difficulties associated with the lack of regulations to the specifications for labeling and packaging.

CANNRA is not the only group that has replied to the request for information. The United States Hemp Roundtable also addressed the panel’s inquiries in a letter. In contrast to CANNRA, the group contended that Congress ought to order the FDA to act, disputing its claim that it lacks the appropriate power to create a cannabinoids regulatory framework.

The ATACH also replied with a letter stating that, although the FDA ought to regulate CBD, unregulated synthetic hemp intoxicants are the real issue. The group argued that the TTB, not the FDA, ought to regulate these goods.

Cornbread Hemp, a CBD company based in Kentucky, also gave the committees its take on the matter. In its view, the absence of FDA regulations has created a fragmented collection of state regulations that adversely affect businesses and perplex consumers.

As these anticipated regulations are codified, the market for the products commercialized by enterprises such as Advanced Container Technologies Inc. (OTC: ACTX) is likely to expand as more entities increase their cannabis production.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — NIH-Funded Research Finds Near Record-Level Use of Cannabis, Hallucinogens, Alcohol by Middle-Aged Adults

Research funded by the National Institutes of Health has revealed historic high levels of cannabis, hallucinogens and alcohol use among adults aged 35 to 50 years old. The NIH-funded study stated that the use of hallucinogens and marijuana by middle-aged adults, which has been on an upward trajectory for several years, peaked in 2022.

Furthermore, younger adults who also took part in the annual Monitoring the Future (MTF) panel study reported record high levels of hallucinogen, cannabis, and vape use. The report showed a significant increase in past-year hallucinogen and cannabis use as well as nicotine vaping in the past five years among adults aged 19 to 30 years old. This age group recorded its highest-ever level of cannabis use and vaping in 2022, the MTF study found.

The study was conducted by researchers from the Institute for Social Research at the University of Michigan and funded by the National Institute on Drug Abuse (NIDA).

Cannabis reform has swept across America in the past two decades and left dozens of state medical and recreational cannabis programs in its wake. Tens of millions of Americans now have access to cannabis, and as lawmakers in several states work on legalizing psychedelics, access to hallucinogenics is steadily increasing.

The report indicated that many adults are turning to cannabis for its therapeutic properties while others have made the plant their social drug in place of alcohol and tobacco. Younger adults continued the trend of moving away from alcohol and exhibited reduced rates of binge drinking over the past decade. On the other hand, middle-aged adults aged 35 to 50 reported the highest binge drinking rates amid major past-year, five-year and 10-year increases in the prevalence of binge drinking.

Specifically, the report noted that 28% of middle-aged adults used cannabis in the past 12 months up from 25% in 2021, an all-time high and more than double the 13% who reported past-year cannabis use in 2012. Past-year psychedelic use in middle-aged adults was also at a record high at 4%, double the 2% in 2021, and substantially more than less than 1% in 2012 and 2017.

Middle-aged adults also reported record high rates of alcohol use. Past-year drinking was up to 85% in 2022 from 83% in 2012 and binge drinking increased to record levels at 29% in 2022 from 26% in 2021, 25% in 2017, and 24% in 2012.

NIDA director Nora Volkow noted that older adults take part in substance use just as much as teens and younger adults. The data collected in this year’s MTF panel study will help the agency better understand drug use trends across people’s lives, the director said, a crucial first step to understanding how substance use and its effects on health evolve over time. Volkow added that the agency wanted to equip younger to older adults with up-to-date information to help them make better-informed substance use-related decisions.

Psychedelics and marijuana are used by some people for medicinal reasons, and companies are looking to standardize therapeutic formulations from cannabis so that these medically oriented users of marijuana can safely address their symptoms while reducing the risks they face from the use of these substances.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.